Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Unternehmen & Branche
| Name | iBio, Inc. |
|---|---|
| Ticker | IBIO |
| CIK | 0001420720 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 26,3 Mio. USD |
| Beta | 1,36 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 0 | -8,993,000 | -0.09 | 64,393,000 | 56,560,000 |
| 2025-09-30 | 10-Q | 100,000 | -5,720,000 | -0.11 | 64,155,000 | 56,039,000 |
| 2025-06-30 | 10-K | 400,000 | -18,377,000 | -1.75 | 23,185,000 | 14,880,000 |
| 2025-03-31 | 10-Q | 0 | -4,861,000 | -0.49 | 19,103,000 | 11,381,000 |
| 2024-12-31 | 10-Q | 200,000 | -4,364,000 | -0.48 | 21,697,000 | 13,895,000 |
| 2024-09-30 | 10-Q | 0 | -3,989,000 | -0.46 | 24,517,000 | 17,754,000 |
| 2024-06-30 | 10-K | 225,000 | -24,907,000 | -6.50 | 28,734,000 | 21,324,000 |
| 2024-03-31 | 10-Q | 50,000 | -3,172,000 | -0.85 | 50,154,000 | 24,863,000 |
| 2023-12-31 | 10-Q | 50,000 | -8,211,000 | -4.42 | 34,022,000 | 9,197,000 |
| 2023-09-30 | 10-Q | 50,000 | -5,746,000 | -4.80 | 37,678,000 | 13,209,000 |
| 2023-06-30 | 10-K | 0 | -65,010,000 | -106.19 | 41,207,000 | 15,381,000 |
| 2023-06-30 | 10-Q | 0 | 41,207,000 | 15,381,000 | ||
| 2023-03-31 | 10-Q | 0 | -7,294,000 | -11.07 | 44,386,000 | 17,389,000 |
| 2022-12-31 | 10-Q | 0 | -33,553,000 | -68.43 | 51,800,000 | 18,823,000 |
| 2022-09-30 | 10-Q | 0 | -18,130,000 | -2.05 | 84,564,000 | 48,368,000 |
| 2022-06-30 | 10-K | 1,884,000 | -50,303,000 | -5.78 | 99,406,000 | 63,485,000 |
| 2022-03-31 | 10-Q | 1,800,000 | -12,390,000 | -1.42 | 115,370,000 | 79,380,000 |
| 2021-12-31 | 10-Q | 0 | -11,920,000 | -1.37 | 126,448,000 | 90,598,000 |
| 2021-09-30 | 10-Q | 84,000 | -8,939,000 | -3.82 | 143,739,000 | 100,543,000 |
| 2021-06-30 | 10-K | 2,371,000 | -23,207,000 | -3.00 | 146,968,000 | 108,585,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.